PL3806895T3 - Przeciwciała, które wiążą się z tkanką nowotworową i ich zastosowania diagnostyczne i terapeutyczne - Google Patents

Przeciwciała, które wiążą się z tkanką nowotworową i ich zastosowania diagnostyczne i terapeutyczne

Info

Publication number
PL3806895T3
PL3806895T3 PL20712121.1T PL20712121T PL3806895T3 PL 3806895 T3 PL3806895 T3 PL 3806895T3 PL 20712121 T PL20712121 T PL 20712121T PL 3806895 T3 PL3806895 T3 PL 3806895T3
Authority
PL
Poland
Prior art keywords
antibodies
diagnostic
tumor tissue
therapeutic uses
bind tumor
Prior art date
Application number
PL20712121.1T
Other languages
English (en)
Inventor
Jeff Defalco
Daniel Eric EMERLING
Jessica FINN
Norman Michael GREENBERG
Vera HUANG
Shaun M. Lippow
Fengling LIU
Amy MANNING-BOG
William H. Robinson
Alexander Scholz
Tito Serafini
Yann Chong TAN
Nikhil VAD
Wayne Volkmuth
Original Assignee
Atreca, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atreca, Inc. filed Critical Atreca, Inc.
Publication of PL3806895T3 publication Critical patent/PL3806895T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL20712121.1T 2019-02-15 2020-02-14 Przeciwciała, które wiążą się z tkanką nowotworową i ich zastosowania diagnostyczne i terapeutyczne PL3806895T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962806310P 2019-02-15 2019-02-15
US201962806285P 2019-02-15 2019-02-15
US201962843298P 2019-05-03 2019-05-03
US201962843751P 2019-05-06 2019-05-06
US201962852830P 2019-05-24 2019-05-24
US201962927501P 2019-10-29 2019-10-29
PCT/US2020/018350 WO2020168231A2 (en) 2019-02-15 2020-02-14 Antibodies that bind tumor tissue for diagnosis and therapy

Publications (1)

Publication Number Publication Date
PL3806895T3 true PL3806895T3 (pl) 2024-02-19

Family

ID=69845562

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20712121.1T PL3806895T3 (pl) 2019-02-15 2020-02-14 Przeciwciała, które wiążą się z tkanką nowotworową i ich zastosowania diagnostyczne i terapeutyczne

Country Status (19)

Country Link
US (2) US11472885B2 (pl)
EP (2) EP4253422A3 (pl)
JP (1) JP7365421B2 (pl)
KR (1) KR102592844B1 (pl)
CN (1) CN114040774A (pl)
AU (1) AU2020223356B2 (pl)
BR (1) BR112021016121A2 (pl)
CA (1) CA3129637A1 (pl)
DK (1) DK3806895T5 (pl)
ES (1) ES2956413T3 (pl)
FI (1) FI3806895T3 (pl)
IL (1) IL285541A (pl)
MX (1) MX2021009727A (pl)
NZ (1) NZ782502A (pl)
PL (1) PL3806895T3 (pl)
PT (1) PT3806895T (pl)
SG (1) SG11202108645YA (pl)
TW (1) TW202045542A (pl)
WO (1) WO2020168231A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230079198A (ko) * 2020-10-05 2023-06-05 프리놈 홀딩스, 인크. 결장 세포 증식성 장애의 조기 검출을 위한 마커
WO2022081843A1 (en) * 2020-10-15 2022-04-21 Atreca, Inc. Antibody scaffold structure
CN113447648B (zh) * 2021-07-01 2022-04-19 浙江大学 检测抗富含丝氨酸/精氨酸剪接因子9-IgG抗体的试剂盒
WO2023010057A1 (en) * 2021-07-28 2023-02-02 Atreca, Inc. Atrc-101 target expression assay
WO2024196777A1 (en) * 2023-03-17 2024-09-26 Memorial Sloan-Kettering Cancer Center Engineered immune cells expressing anti-u5 snrnp200 antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031700A1 (en) 1997-01-21 1998-07-23 The General Hospital Corporation Selection of proteins using rna-protein fusions
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
WO2005040810A1 (en) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Use of protein hnrnp-k as a marker for breast cancer
CA2569788C (en) * 2004-06-10 2014-03-18 Viventia Biotech Inc. Tumor specific antibody
AU2012358181A1 (en) 2011-12-23 2014-07-10 Egen, Inc. Compositions and methods for the delivery of biologically active RNAs
US20150011405A1 (en) 2013-07-03 2015-01-08 Atreca, Inc. Use of Nanoexpression to Interrogate Antigen Repertoires
WO2017010568A1 (ja) 2015-07-16 2017-01-19 国立大学法人京都大学 Ｒｎａ－タンパク質複合体とその使用

Also Published As

Publication number Publication date
BR112021016121A2 (pt) 2022-01-04
JP2022520479A (ja) 2022-03-30
EP3806895A2 (en) 2021-04-21
FI3806895T3 (fi) 2023-09-13
TW202045542A (zh) 2020-12-16
EP4253422A2 (en) 2023-10-04
WO2020168231A3 (en) 2020-09-24
WO2020168231A2 (en) 2020-08-20
DK3806895T5 (da) 2024-08-19
CN114040774A (zh) 2022-02-11
KR102592844B1 (ko) 2023-10-20
NZ782502A (en) 2023-10-27
KR20210139258A (ko) 2021-11-22
US11472885B2 (en) 2022-10-18
SG11202108645YA (en) 2021-09-29
PT3806895T (pt) 2023-07-27
AU2020223356B2 (en) 2023-12-07
DK3806895T3 (da) 2023-07-24
EP3806895B1 (en) 2023-06-21
EP4253422A3 (en) 2023-12-06
US20230140035A1 (en) 2023-05-04
AU2020223356A1 (en) 2021-10-07
MX2021009727A (es) 2021-11-12
US20200325242A1 (en) 2020-10-15
ES2956413T3 (es) 2023-12-20
CA3129637A1 (en) 2020-08-20
IL285541A (en) 2021-09-30
JP7365421B2 (ja) 2023-10-19

Similar Documents

Publication Publication Date Title
SG11202108645YA (en) Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses
IL280707A (en) Diagnostic and therapeutic methods for treating breast cancer
EP4233909A3 (en) Anti-cmet antibody drug conjugates and methods for their use
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL274246A (en) Methods for diagnosing and treating cancer
WO2016055432A3 (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
CA3055791A1 (en) Treatment methods
IL273071A (en) Treatment and diagnosis methods for cancer
CA3045495A1 (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
WO2017049038A3 (en) Anti-cd115 antibodies
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
IL274951A (en) Human antibodies directed against human tissue factor
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
IL286791A (en) Novel proteins that specifically bind psma for cancer diagnosis and treatment
IL284097A (en) FOLR1 binding proteins for cancer diagnosis and treatment
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
EP3740755C0 (en) USE OF THE TAS1R3 PROTEIN AS A MARKER FOR THERAPEUTIC, DIAGNOSTIC AND/OR PROGNOSTIC PURPOSES FOR TUMORS EXPRESSING THIS PROTEIN
IL274177A (en) Medical substances, their preparation and diagnostic method
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
GB201910130D0 (en) Therapeutic and diagnostic target
GB201900408D0 (en) Therapeutic and diagnostic target
GB201900423D0 (en) Therapeutic and diagnostic target
GB201900411D0 (en) Therapeutic and diagnostic target
GB201900401D0 (en) Therapeutic and diagnostic target
GB201900418D0 (en) Therapeutic and diagnostic target